Jundishapur Journal of Microbiology

Published by: Kowsar

Multicenter Identification and Antifungal Susceptibility Patterns of Candida Species Isolated from Clinical Samples

Parisa Badiee 1 , Hamid Badali 2 , Kambiz Diba 3 , Hadis Jafarian 1 , * , Rasoul Mohammadi 4 , Hossein Mirhendi 5 and Mohammad Javad Najafzadeh 6
Authors Information
1 Prof. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Medical Mycology and Parasitology/Invasive Fungi Research Centre (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Cellular and Molecular Research Center, School of Medicine, Urmia University of Medical Sciences, Urmia, IR Iran
4 Department of Medical Parasitology and Mycology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
5 Department of Medical Mycology and Parasitology, School of Public Health and Institute of Health Research, Tehran University of Medical Sciences, Tehran, IR Iran
6 Department of Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Jundishapur Journal of Microbiology: December 2017, 10 (12); e56117
  • Published Online: November 21, 2017
  • Article Type: Research Article
  • Received: June 25, 2017
  • Revised: October 8, 2017
  • Accepted: October 18, 2017
  • DOI: 10.5812/jjm.56117

To Cite: Badiee P, Badali H, Diba K, Jafarian H, Mohammadi R, et al. Multicenter Identification and Antifungal Susceptibility Patterns of Candida Species Isolated from Clinical Samples, Jundishapur J Microbiol. 2017 ; 10(12):e56117. doi: 10.5812/jjm.56117.

Abstract
Copyright © 2017, Jundishapur Journal of Microbiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusion
Acknowledgements
Footnotes
References
  • 1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012; 4(165): 165rv13[DOI][PubMed]
  • 2. Badiee P, Alborzi A, Vojdani R, Shakiba E, Rasouli M, Ravanfar P, et al. Early diagnosis of systemic candidiasis in bone marrow transplant recipients. Exp Clin Transplant. 2010; 8(2): 98-103[PubMed]
  • 3. Colombo AL, Guimaraes T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014; 40(10): 1489-98[DOI][PubMed]
  • 4. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014; 40(9): 1303-12[DOI][PubMed]
  • 5. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010; 36(1): 1-53[DOI][PubMed]
  • 6. Badiee P, Alborzi A, Shakiba E, Farshad S, Japoni A. Susceptibility of Candida species isolated from immunocompromised patients to antifungal agents. East Mediterr Health J. 2011; 17(5): 425-30[PubMed]
  • 7. Lockhart SR, Messer SA, Gherna M, Bishop JA, Merz WG, Pfaller MA, et al. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol. 2009; 47(4): 1216-7[DOI][PubMed]
  • 8. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009; 48(12): 1695-703[DOI][PubMed]
  • 9. CLSI reference method for broth dilution antifungal susceptibility testing of yeasts; approved sandard third edition. CLSI document M27-A3. 2008;
  • 10. CLSI reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. 2012;
  • 11. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol. 2011; 4
  • 12. Badiee P, Amirghofran AA, Nour MG, Shafa M, Nemati MH. Incidence and outcome of documented fungal endocarditis. Int Cardiovasc Res J. 2014; 8(4): 152
  • 13. Ghasemi Z, Hashemi SJ, Rezaei S, Kordbache P, Khosravi M, Mortazavi H, et al. Molecular Analysis of Candida species with Emphasis on Predisposing Factors in Cutaneous Candidiasis Patients. Jundishapur J Microbiol. 2016; 10(2)[DOI]
  • 14. Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol. 2012; 50(12): 3952-9[DOI][PubMed]
  • 15. Haddadi P, Zareifar S, Badiee P, Alborzi A, Mokhtari M, Zomorodian K, et al. Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J Microbiol. 2014; 7(9)[DOI][PubMed]
  • 16. Doi AM, Pignatari AC, Edmond MB, Marra AR, Camargo LF, Siqueira RA, et al. Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program. PLoS One. 2016; 11(1)[DOI][PubMed]
  • 17. Pakshir K, Zomorodian K, Zakaei A, Motamedi M, Rahimi Ghiasi M, Karamitalab M. Molecular identification and in-vitro antifungal susceptibility testing of Candida species isolated from patients with onychomycosis. Curr Med Mycol. 2015; 1(4): 26-32[DOI][PubMed]
  • 18. Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013; 41(3): 655-62[DOI][PubMed]
  • 19. Zomorodian K, Rahimi MJ, Pakshir K, Motamedi M, Ghiasi MR, Rezashah H. Determination of antifungal susceptibility patterns among the clinical isolates of Candida species. J Glob Infect Dis. 2011; 3(4): 357-60[DOI][PubMed]
  • 20. Parisa B, Alborzi A, Shakiba E, Ziyaeyan M, Rasuli M. Molecular Identification and In-Vitro Susceptibility of Candida albicans and C. dubliniensis Isolated from Immu-nocompromised Patients. Iran Red Crescent Med J. 2009; 2009(4): 391-7
  • 21. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, et al. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013; 57(12): 5836-42[DOI][PubMed]
  • 22. Zarei Mahmoudabadi A, Rezaei-Matehkolaei A, Ghanavati F. The susceptibility patterns of Candida species isolated from urine samples to posaconazole and caspofungin. Jundishapur J Microbiol. 2015; 8(3)[DOI][PubMed]
  • 23. Won EJ, Shin JH, Choi MJ, Lee WG, Park YJ, Uh Y, et al. Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage. PLoS One. 2015; 10(2)[DOI][PubMed]
  • 24. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008; 46(1): 120-8[DOI][PubMed]
  • 25. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011; 6(9)[DOI][PubMed]
  • 26. Nett JE, Andes DR. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. Infect Dis Clin North Am. 2016; 30(1): 51-83[DOI][PubMed]
  • 27. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study I. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010; 48(4): 1270-5[DOI][PubMed]
  • 28. Katiraee F, Teifoori F, Soltani M. Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal candidiasis in Iran. Curr Med Mycol. 2015; 1(3): 11-6[DOI][PubMed]
  • 29. Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis. 2015; 82(4): 303-13[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments